BALTIMORE, MD – Marketwired – Aug 20, 2013 – Goldman Small Cap Research, a stock market research firm focused on the small cap and microcap sectors, notes that a research study published by a number of scientists in Italy demonstrates that green tea extracts do have a positive impact in treating malaria, in vitro. While this study predates the recent Plandaí Biotechnology, Inc. (OTCQB: PLPL) malaria study, it nonetheless supports the Company’s series of tests to date that green tea extracts demonstrate an antimalarial effect.

In the Italy-based study, the scientists found that “…a crude extract of green tea as well as two of its main constituents, epigallocatechin-3-gallate (EGCG) and epicatechin gallate (ECG), strongly inhibit Plasmodium falciparum growth in vitro. Both these catechins are found to potentiate the antimalarial effects of artemisinin (a key malaria treatment) without interfering with the folate pathway.” Moreover, the tests showed that the combination of artemisinin and the green tea catechins displayed a strong combined effect.

Interestingly, while in previous studies Plandaí confirmed the same effect, in its most recent tests, the Company recently announced incredible results from its second round of in vitro testing of Phytofare™ Catechin Complex, used to kill the malaria parasite plasmodium falciparum. The results of this independent investigation confirmed a twelve-times greater efficacy in killing the parasite. It should be noted that in this round the Company elected to use the complete Phytofare™ complex and not just the isolated EGCG (Epigallocatechin Gallate) catechin used in earlier studies.

Since malaria is not a disease that affects people in most Western nations, many people are unaware of the reach of this deadly disease which potentially impacts hundreds of millions of people and kills 600,000 in the African continent alone. As a result, success in developing a highly effective commercial botanical extract to treat malaria is a very lucrative and therapeutic opportunity for Plandaí.

To that end, management plans to complete a commercial delivery system by encapsulating Phytofare™ Catechin Complex into a proprietary nano-delivery system that is expected to deliver improved absorption and protection against gut metabolization, allowing the Phytofare™ to remain protected and intact until it reaches the bloodstream.

In addition, further independent scientific investigations of Phytofare™ Catechin Complex, combined with arteseminin which has also been processed into a Phytofare™ extract, will be undertaken both in vitro and in mouse models to validate the extract for oral consumption as an antimalarial drug target. Pending favorable results, the company will seek approval to commence a Phase II human clinical trial.

Goldman Small Cap Research articles and reports on Plandai as well as associated disclaimers can be accessed or downloaded in their entirety by visiting www.goldmanresearch.com.

About Goldman Small Cap Research: Led by former Piper Jaffray analyst and mutual fund manager Rob Goldman, Goldman Small Cap Research produces sponsored and non-sponsored small cap and micro cap stock research reports, articles, daily stock market blogs, and popular investment newsletters. For more information, visit www.goldmanresearch.com.

A Goldman Small Cap Research report is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed. Please read the report’s full disclosures and analyst background on our website before investing. Neither Goldman Small Cap Research nor its parent is a registered investment adviser or broker-dealer with FINRA or any other agency. To download our research, view our disclosures, or for more information, visit www.goldmanresearch.com.

About Plandai Biotechnology, Inc. (OTCQB: PLPL): Plandai Biotechnology, Inc. and its subsidiaries develop highly bioavailable, phytonutrient rich extracts, which are being utilized to deliver a new family of drugs to safely and affordably treat a multitude of diseases and conditions. Plandai Biotechnology controls every aspect of the process, from growing the raw materials on its farms in South Africa, to producing the patented pending Phytofare™ extracts in-house allowing the Company to guarantee the continuity of supply as well as quality control throughout. Targeted industries for the Company’s products include food and beverage, cosmeceutical, wellness, nutraceutical, anti-aging, and pharmaceutical. For more information, please visit http://www.plandaibiotech.com.